Celularity: Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma
Celularity, a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients